Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Clarksterh	10/20/2004 11:12:01 PM
	Read Replies (1) of 1386

CABG and mental impairment literature search: 1) Indicates MMSE (one of the two tests used by Pharmos) will not detect the decline post CABG although other tests might pick it up: ncbi.nlm.nih.gov 2) A very small study actually finds evidence of post operative brain lesions but neuropsychological testing finds nothing measurable. ncbi.nlm.nih.gov 3) Study that indicates memory is particularly sensitive but that in general the impairments are sporadic in the way they affect patients. ncbi.nlm.nih.gov 4)More signs that the best measure of decline is auditory response speed, but hints that other tests may see something. ncbi.nlm.nih.gov 5) The gold standard test of cognitive decline post CABG? (Most referenced study). Note that they defined decline as decline of one SD in any one area and found significant results: ncbi.nlm.nih.gov I think the key take away point from all these studies is that something is happening, but that it is difficult to measure. The most successful single test appears to be auditory, but the best measure is the one used by Duke - looking for decline in any one test of a group of very different tests. This is consistent with the MRI results which show that CABG results in localized ischemic events so that every patient experiencing an event experiences different symptoms. When overall cognitive scores are calculated as the average of all the subscores these declines average out and become invisible (unless a very large patient population is used). So, ... I expect that DEX will show results only if Pharmos does the analysis correctly - grouping the scores into related brain areas and looking for a decline in any one area. But if they do that, and since there actually is hard evidence that the declines are strokelike in nature, I think there is some chance of statistically significant effectivity even in this small trial. Comments? Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next